Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP.2011.4.0-2 | Award Amount: 25.41M | Year: 2011
The mine of the future will exploit mineral raw materials at greater depths than today, requiring completely different approaches compared to todays deep mines, in order to get mineral rights. Only these eco-efficient mines will contribute to improved access to domestic mineral resources, secure the supply of mineral raw materials for Europe and reduce the import dependency. IntelliMine will contribute to realise these concepts of invisible, zero-impact and safe mines. The mine of tomorrow will run an integrated concept. All operations necessary for the eco-efficient provision of the minerals including waste management will be carried out underground. This will drastically reduce the volumes being transported, minimising above ground installations and thus the environmental impact. IntelliMine will develop innovative methods, technologies, machines and equipment for the safe, eco-innovative, intelligent and economical exploitation of mineral raw materials in the EU, including maintenance issues, especially at greater depths. It will investigate autonomous, highly selective mineral extraction processes and machinery based on new sensor technologies as well as innovative concepts for mass flow management and transportation. Such investigations have to be accompanied by rock mechanics and ground control issues as well as health, safety and environmental issues. The concept of an invisible, zero-impact mine requires a refined process underground that selectively extracts the minerals and therefore reduces waste production closer to the mineralisation. Therefore improved near to face processing methods including backfill procedures need to be developed. The necessary level of automation in mining operations can only be achieved by reaching a higher level of integration in all parts of a mine. Fully integrated underground technologies and processes for diagnosis and extraction as well as communication, health and safety issues are the key for the success of the concept.
News Article | February 15, 2017
Fleet Complete kommt nach Österreich und baut sein europäisches Geschäft aus Fleet Complete®, ein führender globaler Anbieter von Technologien für die Flottentelematik und das Mobile-Workforce-Management, hat offiziell seine Partnerschaft mit dem österreichischen Mobilfunkanbieter T-Mobile Austria bekannt gegeben. Die neue Kooperation ermöglicht innovative IoT-Produkte und -Services und bereichert den österreichischen Markt mit einem innovativen Portfolio an Managementlösungen, das Unternehmen eine einheitliche Steuerung und Verbindung ihrer Flottenfahrzeuge, mobilen Geräte und Mitarbeiter im Außendienst bietet. Mit seiner neuen europäischen Zentrale in den Niederlanden ermöglicht Fleet Complete Unternehmen und Flottenmanagern, ihre Produktivität zu verbessern, die Betriebskosten zu senken, effizientere Entscheidungen bei der Planung und Abfertigung zu treffen und das Ergebnis zu optimieren. "Die Suite vereint die Stärken der zwei erstklassigen IoT-Serviceplattformen und stellt so eine überragende Kundenerfahrung sicher", sagt Sjors de Kruijf, VP Sales & Marketing für Fleet Complete Europe. "Wir wissen, welche Bedürfnisse und Herausforderungen unsere Kunden in den Niederlanden, Belgien und Österreich haben. Daher haben wir uns mit dem besten Mobilfunkbetreiber in der Region zusammengeschlossen." "Der Erfolg unserer Kunden ist uns wichtig", sagt Maria Zesch, CCO T-Mobile Austria. "Mit T-Mobile Fleet Complete bieten wir eine integrierte, durchgängige Plattform, die sich ganz flexibel an die Anforderungen unserer Kunden anpassen lässt. In Kombination mit unserem österreichweiten Mobilfunknetz und unserer Infrastruktur bieten wir mit Fleet Complete somit eine Lösung, die deutlichen Mehrwert für unsere Kunden schafft." Mit mehr als 8.000 Kunden weltweit zählt Fleet Complete zu den führenden Anbietern auf dem nordamerikanischen Markt. Dieser Erfolg beruht nicht zuletzt auf zahlreichen exklusiven Partnerschaften mit großen Telekommunikationsanbietern wie Telus in Kanada, AT&T in den USA und Telstra in Australien. Durch die Zusammenarbeit mit T-Mobile Austria profitieren Fleet Complete-Kunden von der Zuverlässigkeit eines großen Mobilfunkanbieters, der über ein sicheres landesweites Netzwerk sowie zahlreiche Vertriebspunkte verfügt und das Fleet Complete-Portfolio an branchenführenden Lösungen und personalisiertem Kundensupport ideal ergänzt. "Wir freuen uns wirklich sehr, T-Mobile als neuen Geschäftspartner in Europa an unserer Seite zu haben", so Tony Lourakis, CEO von Fleet Complete. "Unsere Organisationen haben eine ähnliche Kultur: Wir möchten beide die bestmögliche Kundenerfahrung schaffen und gleichzeitig unsere Kunden dabei unterstützen, erfolgreich zu sein. Ich bin überzeugt davon, dass unsere Kunden in Österreich voll und ganz von dieser Partnerschaft profitieren werden." Das in Toronto ansässige Unternehmen Fleet Complete® ist ein globaler IoT-Anbieter von geschäftskritischen Lösungen für das Flotten-, Asset- und Mobile-Workforce-Management. Seit über sechzehn Jahren stellt Fleet Complete mehr als 8.000 Unternehmen aus aller Welt erstklassige Lösungen für die Disposition, das Flotten-Tracking sowie das mobile Ressourcenmanagement bereit. Mit AT&T in den USA, TELUS in Kanada, Telstra in Australien und T-Mobile in Europa kann das Unternehmen auf wichtige Vertriebspartner zurückgreifen. Fleet Complete zählt in seiner Branche zu den wachstumsstärksten Unternehmen in Nordamerika und hat seit seiner Gründung im Jahr 2000 (damals noch Complete Innovations Inc.) zahlreiche Auszeichnungen für Innovation und Wachstum erhalten. Weitere Informationen finden Sie unter fleetcomplete.com. T-Mobile Austria ist mit 4,3 Millionen Kunden und rund 1.300 Mitarbeitern der zweitgrößte Mobilfunkanbieter Österreichs. Mit den Marken T-Mobile und tele.ring spricht T-Mobile unterschiedliche Zielgruppen an, vom privaten Smartphone-Konsumenten über Ein-Personen-Unternehmen bis zur börsennotierten Aktiengesellschaft. Als Teil der Deutschen Telekom Gruppe profitiert T-Mobile dabei von der Innovationskraft und der finanziellen Stabilität des Konzerns, einem der global größten Player im Telekom-Markt. Im Geschäftsjahr 2015 erzielte der Konzern einen Umsatz von 69,2 Milliarden Euro. T-Mobile Austria fungiert für die gesamte Deutsche Telekom Gruppe u.a. als M2M-Experte (Machine-to-Machine). Für den Geschäftskundenbereich bietet T-Mobile umfangreiche Lösungen durch seine internationale Kompetenz bei Cloud Services an.
News Article | February 28, 2017
Global Liquid Fertilizers market is accounted for $330.38 million in 2015 and is expected to reach $923.56 million by 2022 growing at a CAGR of 15.8%. Increasing demand for food and less yielding capacity of field are triggering the usage of Liquid fertilizers in the field. Its ease of usage, inheritance in precision farming, high efficiency and environment friendly nature are the factors fueling the market. However, less awareness among farmers and huge handling costs are some of the factors holding back the market. Nitrogen segment is estimated to be the largest market type owing to the wide usage of micro and macro nutrients for plant coupled with its easy availability and low cost. Foliar segment is projected to be the fastest application segment attributed to its high compatibility with liquid fertilizers added with high nutrient absorption. Moreover, Asia Pacific is estimated to be the fastest growing market due to its emerging economies, huge agricultural base and favorable government regulations. Huge demand for food products is being met by this region for the people across the globe, which acts as an added advantage to this regional market growth. Some of the key players of the Liquid Fertilizers market includes Agrium Inc., Yara International ASA, Israel Chemical Ltd. (ICL), K+S Aktiengesellschaft, Sociedad Química Y Minera De Chile (SQM), Compo Expert GmbH, Kugler Company, Agroliquid, Plant Food Company, Inc., Haifa Chemicals Ltd. and Rural Liquid Fertilisers (RLF). Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements For more information, please visit http://www.wiseguyreports.com
News Article | February 16, 2017
ALLSCHWIL/BASEL, SWITZERLAND - 16 February 2017 - Actelion Ltd (SIX: ATLN) today announced that Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson (NYSE:JNJ), has published the Offer Prospectus for its previously announced all-cash tender offer to acquire all of the outstanding shares of Actelion for 280 US dollars per share, payable in US dollars, which equates to CHF 280.08 per share as of January 25, 2017, the trading day preceding the announcement of the transaction. The Offer Prospectus is available at: http://www.investor.jnj.com/publictenderoffer.cfm The tender offer is expected to commence on March 3, 2017 and is scheduled to expire at 16:00 hrs Central European Time,10:00 hrs Eastern Standard Time, on March 30, 2017. The tender offer will be open for an initial period of 20 trading days. Johnson & Johnson may extend the main offer period once or several times to a maximum of 40 trading days. The settlement of the tender offer is subject to regulatory approvals and other customary conditions, including the tender of at least 67 percent of all Actelion shares that are issued and outstanding at the end of the offer period. As previously announced, as part of the transaction, immediately prior to the settlement of the tender offer, which is expected to occur by the end of the second quarter of 2017, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company ("R&D NewCo"). The shares of R&D NewCo, which will be listed on the SIX Swiss Exchange (SIX), will be distributed to Actelion's shareholders as a stock dividend immediately prior to settlement of the tender offer. Johnson & Johnson will initially hold 16 percent of the shares of R&D NewCo and have rights to an additional 16 percent of R&D NewCo equity through a convertible note. The offer price will not be reduced as a result of the distribution of the shares of R&D NewCo. Private investors who hold up to 1,000 Actelion shares in a securities account with a custodian bank in Switzerland, and who tender them into the public tender offer, will have the opportunity to elect to receive the USD offer price for their tendered Actelion shares in Swiss francs as further described in the Offer Prospectus. The Actelion board of directors has come to the unanimous conclusion that the offer is in the best interests of Actelion and its shareholders and that the offer price is fair and adequate. The board of directors therefore recommends to the shareholders of Actelion to accept the offer. A report from the Board of Directors and the independent Fairness Opinion are available at: https://www.actelion.com/en/investors/proposed-transaction/index.page GENERAL MEETING OF SHAREHOLDERS The next General Meeting of Shareholders to approve the Business Report of the year ending 31 December 2016, and certain terms of the proposed transaction, is expected to be held on 05 April, 2017. Shareholders holding more than CHF 1,000,000 nominal value of shares, being entitled to add items to the agenda of the general meeting of shareholders, are invited to send in proposals, if any, to Actelion Ltd, attention Corporate Secretary, Gewerbestrasse 16, CH-4123 Allschwil, to arrive no later than 1 March 2017. Any proposal received after the deadline will be disregarded. In order to attend and vote at the General Meeting of Shareholders, shareholders must be registered in the company's shareholder register by 12:00 hrs CET on 31 March, 2017, at the latest. ABOUT JOHNSON & JOHNSON Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. Johnson & Johnson embraces research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Johnson & Johnson's approximately 126,400 employees, at more than 230 Johnson & Johnson operating companies, work with partners in health care to touch the lives of over a billion people every day, throughout the world. ABOUT THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenUS and www.twitter.com/JanssenGlobal. ABOUT ACTELION LTD. Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Founded in late 1997, with now over 2,600 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected by their respective owners. NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential transaction between Johnson & Johnson and Actelion Ltd. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson and Actelion. Risks and uncertainties include, but are not limited to: the satisfaction of closing conditions for the transaction, including clearance by relevant merger control authorities and the receipt of regulatory approvals for the transaction; the possibility that the transaction will not be completed in the expected timeframe or at all; the potential that the expected benefits and opportunities of the transaction, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; economic conditions, including currency exchange and interest rate fluctuations; competition, including technological advances, new products and patents attained by competitors; changes to applicable laws and regulations, including tax laws and domestic and foreign health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and trends toward health care cost containment. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the products, employees/operations and clinical work of Actelion, as well as the ability to ensure continued performance or market growth of Actelion's products. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Actelion can be found in Johnson & Johnson's publicly available filings with the U.S. Securities and Exchange Commission, and Actelion's publicly available filings on its website. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.actelion.com or on request from Johnson & Johnson or Actelion. Neither Johnson & Johnson nor Actelion undertakes to update any forward-looking statement as a result of new information or future events or developments. IMPORTANT ADDITIONAL INFORMATION The public tender offer described herein has not yet commenced. This release is for informational purposes only and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any registered shares in Actelion or Actelion's ADSs, nor shall it form the basis of, or be relied on in connection with, any contract there for. At the time the public tender offer is commenced, shareholders of Actelion are urged to read the offer documents which are available at http://www.investor.jnj.com/publictenderoffer.cfm OFFER RESTRICTIONS The public tender (öffentliches Kaufangebot) offer described in the offer prospectus (the Offer) is not being made and will not be made, directly or indirectly, in any country or jurisdiction in which such an Offer would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Johnson & Johnson or any of its direct or indirect subsidiaries to change or amend the terms or conditions of the Offer in any material way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. It is not intended to extend the Offer to any such country or jurisdiction. Any such documents relating to the Offer must neither be distributed in any such country or jurisdiction nor be sent into such country or jurisdiction, and must not be used for the purpose of soliciting the purchase of securities of Actelion by any person or entity resident or incorporated in any such country or jurisdiction. Notice to U.S. Holders The Offer described in this communication is being made for the registered shares of Actelion, a Swiss corporation (Aktiengesellschaft) whose shares are listed on the SIX Swiss Exchange (SIX), and is subject to Swiss disclosure and procedural requirements, which are different from those of the United States of America (U.S.). The Offer is being made in the U.S. pursuant to Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the U.S. Exchange Act), subject to the exemptions provided by Rule 14d-1 and Rule 14e-5 under the U.S. Exchange Act and any exemptions from such requirements granted by the U.S. Securities and Exchange Commission (the SEC), and otherwise in accordance with the requirements of Swiss law. Accordingly, the Offer is subject to disclosure and other procedural requirements, including with respect to withdrawal rights, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws. U.S. holders of registered shares of Actelion (Actelion Shares) are encouraged to consult with their legal, financial and tax advisors regarding the Offer. The shareholders of Actelion should review the offer prospectus (the Offer Prospectus) and all other Offer documents carefully. The Offer may not be accepted before expiration of a cooling-off period of ten (10) trading days (if not extended by the Swiss Takeover Board), which will run from the trading day immediately after the publication date of the Offer Prospectus. According to the laws of Switzerland, Actelion Shares tendered into the Offer may generally not be withdrawn after they are tendered except under certain circumstances, in particular if a competing offer for the Actelion Shares is launched. In accordance with the laws of Switzerland and subject to applicable regulatory requirements, Johnson & Johnson and its subsidiaries and affiliates or their respective nominees or brokers (acting as agents for Johnson & Johnson, its subsidiaries or affiliates) may from time to time after the date of the Offer Prospectus, and other than pursuant to the Offer, directly or indirectly, purchase or arrange to purchase Actelion Shares or any securities that are convertible into, exchangeable for or exercisable for Actelion Shares from shareholders of Actelion who are willing to sell their Actelion Shares outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, and shall comply with applicable laws and regulations in Switzerland and applicable U.S. securities regulation and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act. Any such purchases will not be made at prices higher than the offer price or on terms more favorable than those offered pursuant to the Offer unless the offer price is increased accordingly. Any information about such purchases or arrangements to purchase will be publicly disclosed in the U.S. on Johnson & Johnson's website to the extent that such information is made public in accordance with the applicable laws and regulations of Switzerland. In addition, the financial advisor to Actelion and, subject to applicable Swiss and U.S. regulation and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act, the financial advisor to Johnson & Johnson and its affiliates may also engage in ordinary course trading activities in securities of Actelion, which may include purchases or arrangements to purchase such securities. It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. securities laws, since the Offeror and Actelion are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment. The receipt of cash pursuant to the Offer by a U.S. holder of Actelion Shares may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. In addition, the receipt of shares of R&D NewCo pursuant to the demerger distribution by a U.S. holder of Actelion Shares may be taxable as a dividend for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. Each shareholder of Actelion is urged to consult his or her independent professional advisor immediately regarding the tax consequences of an acceptance of the Offer. Neither the SEC nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer, (b) passed upon the merits or fairness of the Offer, or (c) passed upon the adequacy or accuracy of the disclosure in the Offer Prospectus. Any representation to the contrary is a criminal offence in the U.S. American Depositary Shares and American Depositary Receipts Johnson & Johnson, its subsidiaries and affiliates are aware that there are "unsponsored" American Depositary Receipt Programs concerning Actelion Shares. The Offer is not being made for American Depositary Shares representing Actelion Shares (ADSs), nor for American Depositary Receipts evidencing such ADSs (ADRs). However, the Offer is being made for the Actelion Shares that are represented by the ADSs. Holders of ADSs and ADRs are encouraged to consult with the appropriate depositary regarding the tender of Actelion Shares that are represented by ADSs. Johnson & Johnson, its subsidiaries and affiliates are unaware of whether any respective depositary will make arrangements to tender the underlying Actelion Shares into the Offer on behalf of holders of ADSs or ADRs. Holders of ADSs may present their ADSs to the appropriate depositary for cancellation and (upon compliance with the terms of the deposit agreements relating to the "unsponsored" American Depositary Receipt Program concerning Actelion Shares, including payment of the depositary's fees and any applicable transfer fees, taxes and governmental charges) delivery of Actelion Shares to them, in order to become shareholders of Actelion. The Offer may then be accepted in accordance with its terms for the Actelion Shares delivered to holders of ADSs upon such cancellation. Holders of ADSs should be aware, however, that in order to tender in this manner, they may need to have an account in Switzerland into which the Actelion Shares can be delivered. For further information please contact: Andrew Weiss Senior Vice President, Head of Investor Relations & Corporate Communications Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 www.actelion.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Ks Aktiengesellschaft | Date: 2011-12-21
The invention presented concerns a process for the manufacture of coated, nano-scale, hydrotalcites, where the individual, primary, nano-scale hydrotalcite particles are coated. In order to obtain the corresponding hydrotalcite particles in coated, nano-scale form, the additive precipitation reaction is employed invention-related. Every primary particle indicates its own coating in this case. In a further aspect, the registration is directed toward coated primary, nano-scale, hydrotalcite particles, in particular obtainable in accordance with the invention-related process. A further aspect of the invention is directed toward composites containing nano-scale hydrotalcites, in particular hydrotalcites manufactured in accordance with the invention presented. Finally the registration presented is directed towards compositions containing mixtures of magnesium hydroxide and hydrotalcite.
Ks Aktiengesellschaft | Date: 2016-05-23
This invention concerns microorganisms, to be precise Archaea, which, in case of cultivation at 25 C., indicate unsaturated ether lipids in quantities of at least 10% with reference to the total amount of ether lipids. In a further aspect, this invention is directed towards microorganisms within the Archaea, in particular from those of the class halomebacteria, in particular the order of Halobacteriales, in particular the family Halobacteriaceae, in particular the genus Haloarcula and Haloferax containing lipid compositions. These lipid compositions, in particular liposomes, are characterized by the presence of large quantities of unsaturated ether lipids. In a further aspect, the existing invention concerns a process for the extraction of these unsaturated ether lipids from the designated Archaea.
Electrostatic Separation Of A Mixture Of Valuable Materials, E.G., A Mineral Salt Mixture, By Means Of A Pipe Separator, And Device For Electrostatically Separating Such A Mixture Of Valuable Materials By Means Of A Pipe Separator, And Method For Electrostatic Separation
Ks Aktiengesellschaft | Date: 2011-03-01
The invention relates to a pipe separator (5) for electrostatically separating particles of a mixture of valuable materials, e.g., a mineral salt mixture, having different electrical charges, comprising a carrier pipe (10), wherein the carrier pipe has two field electrodes (8, 9) arranged opposite each other for generating an electric field, wherein the field electrodes (8, 9) are covered toward the inside by an insulating layer.
Ks Aktiengesellschaft | Date: 2013-12-20
The present invention relates to compositions containing at least 80% by weight, especially at least 90% by weight, based on the total weight of the composition, of at least one magnesium sulfate-urea compound selected from the compound of the formula (I) and mixtures of the compound of the formula (I) with the compound of the formula (II): [MgSO_(4).mCO(NH_(2))_(2).nH_(2)O] (I), [MgSO_(4).xCO(NH_(2))_(2).yH_(2)O] (II), in which m and x are each in the range from 0.9 to 1.1, n is in the range from 1.9 to 2.1 and y is in the range from 2.9 to 3.1, where the compositions, based on the total weight of the composition, contain less than 10% by weight of free MgSO_(4 )in the form of the anhydrate or in the form of hydrates of magnesium sulfate and less than 10% by weight of unbound urea. The invention also relates to the production of the compositions and to the use thereof as fertilizers or fertilizer additive.
Ks Aktiengesellschaft | Date: 2013-04-19
The invention relates to a method for reducing the losses of valuable substances in mineral processing, wherein a mineral mixture, dry or suspended, has a grain fraction with a tailings portion and a superficial valuable material portion after a first separation stage, and the tailings portion quantitatively exceeds the valuable material portion, the mineral mixture being suspended, insofar as it is not already a suspension, for the agglomeration of grains of the grain fraction with the valuable material portion, and a substantially hydrophobic agent with a content of anionic or cationic amphiphilic molecules is added to the suspended mineral mixture in order to wet the surface of the valuable substance portion to form agglomeration bridges between the valuable material portions of the grains, wherein the mineral mixture is routed in a solution saturated with the valuable material portion and the tailings to a wet separation stage for classification into a fraction richer in valuable material and a fraction less rich in valuable material, wherein separation in the wet separation stage is performed with the aid of a liquid film flow, the fraction richer in valuable material discharged from the wet separation stage being wet-ground, and the wet-ground fraction being fed to a further classification stage.
Ks Aktiengesellschaft | Date: 2014-06-12
(EN) The invention relates to a special LIBS measurement tube focusing unit, referred to simply as LIBS measurement tube, for vertically dipping into a material to be analyzed, which material is moved in a horizontal flow, characterized in that the measurement tube extends vertically and is internally hollow and open at least at the bottom end, such that a bottom edge is formed at the bottom end, the measurement tube has an inlet for coupling in a laser beam and an outlet for coupling out an emission spectrum at the upper end, the measurement tube is constructed in such a way that, in the measurement tube, the laser beam is focused at the material to be analyzed, specifically bulk material, in particular raw, intermediate, and end products from the processing of potash, magnesium, rock salt, or evaporated salt, but without additional scattering and deflection occurring, such that a plasma of the material to be analyzed is produced within the measurement tube by the laser radiation and the emission spectrum of the material to be analyzed reaches the outlet for outcoupling through the interior of the measurement tube, and scrapers (1, 2) lie on the inner and outer focusing tube wall annularly, preferably at the same vertical height on the focusing tube (3), which scrapers are arranged in such a way that the scrapers can be moved vertically in relation to the focusing tube (3), such that material to be analyzed that adheres to the focusing tube (3) on the inside and outside in the lower region can be scraped off by a relative motion of the focusing tube (3) in relation to the scrapers (1, 2).